2515 MCKINNEY AVE #1000, DALLAS, TX
Announces 2026 Second Quarter Financial Results
Names Darcy Bajko Chief Commercial Officer to Lead Global Sales Launch of FDA-Cleared DeepView® System for Burn Indication
Announces Voting Results of Annual Meeting of Stockholders
Receives FDA De Novo Clearance for DeepView® System for Burn Indication
Offers Employment to Mr. Vincent S. Capone as Chief Executive Officer
Names David McGuire, CPA, as Chief Financial Officer
Earnings Release
Awarded $31.7 Million of BARDA Funding to Accelerate Development of the DeepView® System
Q2
Q1
FY 2025
Q3
FY 2024
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Amended Registration Statement for Securities Offered under a Shelf Registration
Effectiveness Notice
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Correspondence
Submission Upload